Takeda's Interest Likely To Flush Out Further Shire Suitors

As Takeda discloses that it is considering making a bid to acquire Shire, other big pharma companies look likely to assess their own interest in the firm. Pfizer and AbbVie are among those that may lay their cards on the table.

SC1803_Peacock_ 133503560_1200.jpg
Takeda may emerge as a suitor for Shire: but will it be alone? • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.'s statement that it is considering making an approach to Shire PLC may force the hand of other big pharma companies. Several firms, including Pfizer Inc. and AbbVie Inc., are viewed as in the market for larger transactions as they face increased pressure on their current growth prospects, and Shire's position at the lower end of the large biopharma set makes it a more digestible, but still transformative target for the biggest companies in the sector.

Furthermore, with Takeda already carrying debt and of a similar market cap size to Shire, it is quite possible that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.